<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142372</url>
  </required_header>
  <id_info>
    <org_study_id>R19060B</org_study_id>
    <nct_id>NCT04142372</nct_id>
  </id_info>
  <brief_title>Tissue Microarray of Hematological Malignancies</brief_title>
  <acronym>HemaTMA</acronym>
  <official_title>Tissue Microarray of Hematological Malignancies: Search for Novel Regulators of Disease Pathology Across Disease Entities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to create new tools for improving management of patients with
      hematological malignancies by combining extensive clinical data from patients newly diagnosed
      with hematological malignancies and innovative laboratory analyses made on available tissue
      samples in regional biobanks from these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firstly, clinical information is collected on all hematological malignancies diagnosed in our
      hospital district area retrospectively between the years 2000 and 2019. Clinical outcomes,
      laboratory results, clinically relevant diagnoses, characteristics defining clinical stage
      and established prognostic parameters are gathered.

      Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using
      representative annotated tissue areas. This TMA is used in combination with additional
      control material to identify prognostic and predictive biomarkers.

      A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out
      genes of possible drug targets, disease specific markers, prognostic markers, or predictive
      markers.

      The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools
      for prognostication and diagnostics, and targets for treatment. Artificial intelligence
      -assisted differential diagnostics will be tested.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Time from the first line treatment for hematological malignancy until the date of first documented relapse or transformation or death of any cause, whichever came first, assessed up to the end of the study period (April 2019).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the diagnosis up to the end of the study period (April 2019).</time_frame>
    <description>Survival time from the diagnosis of hematological malignancy until the date of death of any cause, assessed up to the end of the study period (April 2019).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Best response to the first line treatment for the hematological malignancy, according to malignancy in question, e.g. complete response (CR), stringent complete response (sCR), partial response (PR), very good partial response (VGPR), stable disease (SD), progressive disease (PD), treatment failure, clinical response, hematological response etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Survival time from the first line treatment for hematological malignancy until any primary event (death, relapse, disease progression/transformation, secondary malignancy, resistant disease etc.), whichever came first, assessed up to the end of the study period (April 2019).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sepsis or other life-threatening infection</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Fulminant infection after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple organ failure</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Altered organ function in acutely ill patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombo-embolism</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Venous thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease transformation</measure>
    <time_frame>From the diagnosis up to the end of the study period (April 2019).</time_frame>
    <description>Hematological malignancy transforms into another malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Admission to intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Treatment-related adverse effects/events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary malignancy</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Secondary malignancy after the diagnosis of hematological malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Relapse after or during the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Complete remission after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete remission</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Time to complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Best response e.g. hematological remission, molecular remission, radiological remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>From the first line treatment up to the end of the study period (April 2019).</time_frame>
    <description>Time to best response e.g. hematological remission, molecular remission, radiological remission</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hematological Malignancies</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Diagnostic samples containing cells and tissues.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with new hematological malignancies 1.1.2000- 30.4.2019
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hematological malignancy/neoplasm

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Artturi Mäkinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olli Lohi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Merja Heinäniemi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Vänskä, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiina Lyly-Yrjänäinen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere Univerisity Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33270</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Matti Vänskä</investigator_full_name>
    <investigator_title>Principal Investigator, MD PhD</investigator_title>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>biomarker</keyword>
  <keyword>prognosis</keyword>
  <keyword>myeloma</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>myeloproliferative disorder</keyword>
  <keyword>diagnostics</keyword>
  <keyword>tissue microarray</keyword>
  <keyword>proteomics</keyword>
  <keyword>genomics</keyword>
  <keyword>clinical outcome</keyword>
  <keyword>biobanking</keyword>
  <keyword>digitalization</keyword>
  <keyword>data mining</keyword>
  <keyword>hematology</keyword>
  <keyword>oncology</keyword>
  <keyword>pathology</keyword>
  <keyword>bioinformatics</keyword>
  <keyword>real world data</keyword>
  <keyword>hematological malignancy</keyword>
  <keyword>survival</keyword>
  <keyword>treatment response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

